[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,511,607
  • Shares Outstanding, K 356,511
  • Annual Sales, $ 9,680 K
  • Annual Income, $ -250,640 K
  • EBIT $ -90 M
  • EBITDA $ -85 M
  • 60-Month Beta 1.07
  • Price/Sales 156.09
  • Price/Cash Flow N/A
  • Price/Book 74.70

Options Overview Details

View History
  • Implied Volatility 77.92% (+12.41%)
  • Historical Volatility 54.32%
  • IV Percentile 3%
  • IV Rank 10.03%
  • IV High 256.48% on 08/14/25
  • IV Low 58.01% on 05/15/26
  • Expected Move (DTE 22) 0.82 (19.45%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6,744
  • Volume Avg (30-Day) 2,152
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 51,689
  • Open Int (30-Day) 51,528
  • Expected Range 3.42 to 5.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.00
  • Number of Estimates 2
  • High Estimate $0.01
  • Low Estimate $-0.01
  • Prior Year $-0.11
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.92 +10.08%
on 04/29/26
4.87 -11.40%
on 05/14/26
+0.36 (+8.96%)
since 04/27/26
3-Month
3.04 +41.94%
on 03/25/26
4.87 -11.40%
on 05/14/26
+0.53 (+13.85%)
since 02/27/26
52-Week
1.28 +237.11%
on 06/03/25
5.47 -21.04%
on 02/17/26
+2.91 (+206.03%)
since 05/27/25

Most Recent Stories

More News
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

GERMANTOWN, Md. , May 27, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...

PGEN : 4.32 (+1.77%)
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference

GERMANTOWN, Md. , May 26, 2026 /PRNewswire/ -- Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.32 (+1.77%)
Precigen Q1 Earnings Call Highlights

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.On...

PGEN : 4.32 (+1.77%)
Precigen Reports First Quarter 2026 Financial Results and Business Updates

GERMANTOWN, Md. , May 13, 2026 /PRNewswire/ --  Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.32 (+1.77%)
Precigen's First Commercial Quarter Will Test Whether PAPZIMEOS Revenue Can Justify the Pivot

Barchart Research What to Expect from PGEN Earnings PGEN Generated May 12, 2026 Current Price $4.08 EPS Estimate $$-0.03 Consensus Rating Moderate Buy Average Move 9.60% Precigen's First Commercial Quarter...

PGEN : 4.32 (+1.77%)
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

GERMANTOWN, Md. , May 7, 2026 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.32 (+1.77%)
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

GERMANTOWN, Md. , March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.32 (+1.77%)
Precigen Reports Full Year 2025 Financial Results and Business Updates

GERMANTOWN, Md. , March 25, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.32 (+1.77%)
Precigen Faces Mounting Losses as Analysts Brace for Widening Deficit

PGEN : 4.32 (+1.77%)
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

GERMANTOWN, Md. , March 11, 2026 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.32 (+1.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional...

See More

Key Turning Points

3rd Resistance Point 4.59
2nd Resistance Point 4.48
1st Resistance Point 4.36
Last Price 4.32
1st Support Level 4.13
2nd Support Level 4.02
3rd Support Level 3.90

See More

52-Week High 5.47
Last Price 4.32
Fibonacci 61.8% 3.87
Fibonacci 50% 3.37
Fibonacci 38.2% 2.88
52-Week Low 1.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.